Product logins

Find logins to all Clarivate products below.


Chronic Pain – Current Treatment – Current Treatment: Physician Insights – Chronic Pain (US)

The treatment of chronic pain continues to provide unique challenges to physicians owing to the heterogeneity of pain pathophysiology within and across different chronic pain subtypes and the absence of targeted mechanism-based therapies. As a result, it is difficult to achieve adequate analgesia in all patients despite the extensive armamentarium of chronic pain therapies, including the increasing availability of cost-effective generic treatments. The high cost of chronic pain management stemming from a long duration of treatment and the many lines of therapy often required to maintain analgesic effects are exacerbated by the growth of the market due in part to the increasing prevalence of key population segments, including osteoarthritis pain and chronic back pain. Unfortunately, no truly novel analgesic solutions for chronic pain have launched in recent years. Fixed-dose combinations of nonsteroidal anti-inflammatory drugs and abuse-deterrent formulations of opioid analgesics offer incremental advantages in safety and tolerability but struggle to compete against long-generic and firmly entrenched standards of care.

Questions Answered

  • How is chronic pain being treated in the United States today, and what are the drivers and constraints influencing physicians’ treatment decisions?
  • What factors drive switching between or discontinuation of select analgesics?
  • What impact has the COVID-19 pandemic had on the prescribing of analgesics for chronic pain?
  • What impact has the more-recent launch of Burke’s Consensi (branded celecoxib / amlodipine) had on physician prescribing behavior for chronic pain?

Content Highlights

Geography: United States

Primary research: Survey of 51 U.S. primary care physicians and 51 U.S. pain specialists

Key drugs covered: Hysingla ER, OxyContin, Nucynta ER, Belbuca, Xtampza ER, Consensi, pregabalin, celecoxib, diclofenac topical gel

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Related Market Assessment Reports

Report
Gene Therapy – Access & Reimbursement – Access & Reimbursement – Gene Therapies for Rare Diseases (US)
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel reimbursement approaches are rapidly gaining importance. To assist developers of gene…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder of the hair follicles, characterized by painful, inflamed lesions often filled with fluid or pus. AbbVie’s Humira (…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein…
Report
Obesity – Current Treatment – Treatment Algorithms: Claims Data Analysis – Obesity (US)
GLP-1 RA products have set new standards for weight-loss drugs and are driving the rapid growth of the obesity market. Novo Nordisk’s semaglutide (Wegovy) and Eli Lilly’s tirzepatide (Zepbound…